{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:47:38Z","timestamp":1787032058289,"version":"build-2736575974"},"reference-count":95,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.5551\/jat.rv22037","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:07:19Z","timestamp":1748455639000},"page":"911-923","source":"Crossref","is-referenced-by-count":8,"title":["Cholesteryl Ester Transfer Protein Deficiency and Hyperalphalipoproteinemia"],"prefix":"10.5551","volume":"32","author":[{"given":"Akihiro","family":"Inazu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mabuchi H: Half a century tales of familial hypercholesterolemia (FH) in Japan. J Atheroscler Thromb, 2017; 24: 189-207","DOI":"10.5551\/jat.RV16008"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, Daida H, Dobashi K, Hayashi T, Hori M, Matsuki K, Minamino T, Yokoyama S, Harada-Shiba M: Homozygous familial hypercholesterolemia. J Atheroscler Thromb, 2021; 28: 665-678","DOI":"10.5551\/jat.RV17050"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, Itoh H, Sakai Y, Sakai T, Ueda K, Takeda R: Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia.Atherosclerosis, 1985; 58: 175-186","DOI":"10.1016\/0021-9150(85)90064-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R, Tall AR: Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature, 1989; 342: 448-451","DOI":"10.1038\/342448a0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med, 1990; 323; 1234-1238","DOI":"10.1056\/NEJM199011013231803"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122","DOI":"10.1056\/NEJMoa0706628"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099","DOI":"10.1056\/NEJMoa1206797"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators: Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med, 2017; 376: 1933-1942","DOI":"10.1056\/NEJMoa1609581"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ; HPS3\/TIMI55\u2013REVEAL Collaborative Group: Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med, 2017; 377: 1217-1227","DOI":"10.1056\/NEJMoa1706444"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ridker PM, Pare G, Parker AN, Zee RYL, Miletich JP, Chasman DI: Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction. Genomewide analysis among 18245 initially healthy women from the Women\u2019s Genome Health Study. Circ Cardiovasc Genet, 2009; 2: 26-33","DOI":"10.1161\/CIRCGENETICS.108.817304"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjaerg-Hansen A: Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. Journal of the American College of Cardiology, 2012; 60: 2041-2048","DOI":"10.1016\/j.jacc.2012.07.045"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Takata M, Inazu A, Katsuda S, Miwa K, Kawashiri MA, Nohara A, Higashikata T, Kobayashi J, Mabuchi H, Yamagishi M: CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia. Clin Sci (Lond), 2006; 111: 325-331","DOI":"10.1042\/CS20060088"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D\u2019Agostino RB, Ordovas JM: Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation, 2009; 120: 2414-2420","DOI":"10.1161\/CIRCULATIONAHA.109.872705"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hiura Y, Shen CS, Kokubo Y, Okamura T, Morisaki T, Tomoike H, Yoshida T, Sakamoto H, Goto Y, Nonogi H, Iwai N: Identification of genetic markers associated with high-density lipoprotein-cholesterol by genome-wide screening in a Japanese population. The Suita Study. Circ J, 2009; 73: 1119-1126","DOI":"10.1253\/circj.CJ-08-1101"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Takeuchi F, Isono M, Katsuya T, Yokota M, Yamamoto K, Nabika T, Shimokawa K, Nakashima E, Sugiyama T, Rakugi H, Yamaguchi S, Ogihara T, Yamori Y, Kato N: Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals. PLoS One, 2012; 7: e46385","DOI":"10.1371\/journal.pone.0046385"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Inazu A, Quinet EM, Wang S, Brown ML, Stevenson S, Barr ML, Moulin P, Tall AR: Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry, 1992; 31: 2352-2358","DOI":"10.1021\/bi00123a021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Papp AC, Pinsonneault JK, Wang D, Newman LC, Gong Y, Johnson JA, Pepine CJ, Kumari M, Hingorani AD, Talmud PJ, Shah S, Humphries SE, Sadee W: Cholesteryl ester transfer protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One, 2012; 7: e31930","DOI":"10.1371\/journal.pone.0031930"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Suhy A, Hartmann K, Newman L, Papp A, Toneff T, Hook V, Sadee W: Genetic variants affecting alternative splicing of human cholesteryl ester transfer protein. Biochem Biophys Res Commu, 2014; 443: 1270-1274","DOI":"10.1016\/j.bbrc.2013.12.127"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J: Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA, 2008 ; 299: 2777-2788","DOI":"10.1001\/jama.299.23.2777"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Cheng CY, Yamashiro K, Chen LJ, Ahn J, Huang L, Huang L, Cheung CM, Miyake M, Cackett PD, Yeo IY, Laude A, Mathur R, Pang J, Sim KS, Koh AH, Chen P, Lee SY, Wong D, Chan CM, Loh BK, Sun Y, Davila S, Nakata I, Nakanishi H, Akagi-Kurashige Y, Gotoh N, Tsujikawa A, Matsuda F, Mori K, Yoneya S, Sakurada Y, Iijima H, Iida T, Honda S, Lai TY, Tam PO, Chen H, Tang S, Ding X, Wen F, Lu F, Zhang X, Shi Y, Zhao P, Zhao B, Sang J, Gong B, Dorajoo R, Yuan JM, Koh WP, van Dam RM, Friedlander Y, Lin Y, Hibberd ML, Foo JN, Wang N, Wong CH, Tan GS, Park SJ, Bhargava M, Gopal L, Naing T, Liao J, Ong PG, Mitchell P, Zhou P, Xie X, Liang J, Mei J, Jin X, Saw SM, Ozaki M, Mizoguchi T, Kurimoto Y, Woo SJ, Chung H, Yu HG, Shin JY, Park DH, Kim IT, Chang W, Sagong M, Lee SJ, Kim HW, Lee JE, Li Y, Liu J, Teo YY, Heng CK, Lim TH, Yang SK, Song K, Vithana EN, Aung T, Bei JX, Zeng YX, Tai ES, Li XX, Yang Z, Park KH, Pang CP, Yoshimura N, Wong TY, Khor CC: New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nature Commu, 2015; 6: 6063","DOI":"10.1038\/ncomms7063"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Curcio CA, Johnson M, Huang J-D, Rudolf M: Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Progress in Retinal and Eye Research, 2009; 28: 393-422","DOI":"10.1016\/j.preteyeres.2009.08.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nordestgaard LT, Christoffersen M, Lauridsen BK, Afzal S, Nordestgaard BG, Frikke-Schmidt R, Tybj\u00e6rg-Hansen A: Long-term Benefits and Harms Associated with Genetic Cholesteryl Ester Transfer Protein Deficiency in the General Population. JAMA Cardiol, 2022; 7: 55-64","DOI":"10.1001\/jamacardio.2021.3728"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Hirano K-i, Nagasaka H, Kobayashi K, Yamaguchi S, Suzuki A, Toda T, Doyu M: Disease-associated marked hyperalphalipoproteinemia. Molecular Genet Metabolism Reports, 2014; 1: 264-268","DOI":"10.1016\/j.ymgmr.2014.06.001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR: A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res, 2004; 45: 948-953","DOI":"10.1194\/jlr.M300520-JLR200"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nomura A, Won HH, Khera AV, Takeuchi F, Ito K, McCarthy S, Emdin CA, Klarin D, Natarajan P, Zekavat SM, Gupta N, Peloso GM, Borecki IB, Teslovich TM, Asselta R, Duga S, Merlini PA, Correa A, Kessler T, Wilson JG, Bown MJ, Hall AS, Braund PS, Carey DJ, Murray MF, Kirchner HL, Leader JB, Lavage DR, Manus JN, Hartze DN, Samani NJ, Schunkert H, Marrugat J, Elosua R, McPherson R, Farrall M, Watkins H, Juang JJ, Hsiung CA, Lin SY, Wang JS, Tada H, Kawashiri MA, Inazu A, Yamagishi M, Katsuya T, Nakashima E, Nakatochi M, Yamamoto K, Yokota M, Momozawa Y, Rotter JI, Lander ES, Rader DJ, Danesh J, Ardissino D, Gabriel S, Willer CJ, Abecasis GR, Saleheen D, Kubo M, Kato N, Ida Chen YD, Dewey FE, Kathiresan S: Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease. Circ Res, 2017; 121: 81-88","DOI":"10.1161\/CIRCRESAHA.117.311145"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Lee CJ, Park MS, Kim M, Ann SJ, Lee J, Park S, Kang SM, Jang Y, Lee JH, Lee SH: CETP, LIPC, and SCARB1 variants in individuals with extremely high high-density lipoprotein-cholesterol levels. Sci Rep, 2019; 9: 10915","DOI":"10.1038\/s41598-019-47456-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Inazu A, Jiang X-C, Haraki T, Yagi K, Kamon N, Koizumi J, Mabuchi H, Takeda R, Takata K, Moriyama Y, Doi M, Tall A: Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest, 1994; 94; 1872-1882","DOI":"10.1172\/JCI117537"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Ohtani R, Inazu A, Noji Y, Wakasugi T, Miwa K, Tada H, Kawashiri M, Noguchi T, Nohara A, Kobayashi J, Koizumi J, Yamagishi M, Mabuchi H: Novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic subjects. Clin Chim Acta, 2012; 413: 537-543","DOI":"10.1016\/j.cca.2011.11.010"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Izem L, Greene DJ, Bialkowska K, Morton RE: Overexpression of full-length cholesteryl ester transfer protein in SW872 cells reduces lipid accumulation. J Lipid Res, 2015; 56: 515-525","DOI":"10.1194\/jlr.m053678"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Qi Q, Durst R, Schwarzfuchs D, Leitersdorf E, Shpitzen S, Li Y, Wu H, Champagne CM, Hu FB, Stampfer MJ, Bray GA, Sacks FM, Shai I, Qi L: CETP genotype and changes in lipid levels in response to weight-loss diet intervention in the POUNDS LOST and DIRECT randomized trials. J Lipid Res, 2015; 56: 713-721","DOI":"10.1194\/jlr.P055715"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Teran-Garcia M, Despres J-P, Tremblay A, Bouchard C: Effects of cholesterol ester transfer protein (CETP) gene on adiposity in response to long-term overfeeding. Atherosclerosis, 2008; 196: 455-460","DOI":"10.1016\/j.atherosclerosis.2006.12.005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Dorighello GG, Assis LHP, Rentz T, Morari J, Santana MFM, Passarelli M, Ridgway ND, Vercesi AE, Oliveira HCF: Novel role of CETP in macrophages: Reduction of mitochondrial oxidants production and modulation of cell immune-metabolic profile. Antioxidants, 2022; 11: 1734","DOI":"10.3390\/antiox11091734"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Inazu A, Nakajima K, Nakano T, Niimi M, Kawashiri M, Nohara A, Kobayashi J, Mabuchi H: Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency. Atherosclerosis, 2008; 196: 953-957","DOI":"10.1016\/j.atherosclerosis.2007.02.028"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Huang Y, von Eckardstein A, Wu S, Assmann G: Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest, 1995; 96: 2693-2701","DOI":"10.1172\/JCI118336"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Heeren J, Grewal T, Laatsch A, Becker N, Rinninger F, Rye KA, Beisiegel U: Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J Biol Chem, 2004; 279: 55483-55492","DOI":"10.1074\/jbc.M409324200"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Altenburg M, Johnson L, Wilder J, Maeda N: Apolipoprotein E4 in macrophages enhances atherogenesis in a low density lipoprotein receptor-dependent manner. J Biol Chem, 2007; 282: 7817-7824","DOI":"10.1074\/jbc.M610712200"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kypreos KE, Zannis VI: Pathway of biogenesis of apolipoprotein E-containg HDL in vivo with the participation of ABCA1 and LCAT. Biochem J, 2007; 403; 359-367","DOI":"10.1042\/BJ20061048"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Gibson JC, Rubinstein A, Bukberg PR, Brown WV: Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res, 1983; 24: 886-898","DOI":"10.1016\/S0022-2275(20)37934-7"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Farkas MH, Swift LL, Hasty AH, Linton MF, Fazio S: The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem, 2003; 278: 9412-9417","DOI":"10.1074\/jbc.M208026200"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Ji ZS, Dichek HL, Miranda RD, Mahley RW: Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem, 1997; 272: 31285-31292","DOI":"10.1074\/jbc.272.50.31285"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Abalain JH, Carre JL, Leglise D, Robinet A, Legall F, Meskar A, Floch HH, Colin J: Is age-related macular degeneration associated with serum lipoprotein and lipoparticle levels? Clin Chim Acta, 2002; 326: 97-104","DOI":"10.1016\/S0009-8981(02)00288-7"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Curcio CA, Johnson M, Huang JD, Rudolf M: Apolipoprotein B-containing lipoproteins in retinal aging and age-related macular degeneration. J Lipid Res, 2010; 51: 451-467","DOI":"10.1194\/jlr.R002238"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Grubaugh CR, Dhingra A, Prakash B, Montenegro D, Sparrow JR, Daniele LL, Curcio CA, Bell BA, Hussain MM, Boesze-Battaglia K: Microsomal triglyceride transfer protein is necessary to maintain lipid homeostasis and retinal function. FASEB J, 2024; 38: e23522","DOI":"10.1096\/fj.202302491R"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY: Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest, 1990; 86: 688-695","DOI":"10.1172\/JCI114764"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Chiba H, Akita H, Tsuchihashi K, Hui SP, Takahashi Y, Fuda H, Suzuki H, Shibuya H, Tsuji M, Kobayashi K: Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. J Lipid Res, 1997; 38: 1204-1216","DOI":"10.1016\/S0022-2275(20)37202-3"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Oliveira HC, Ma L, Milne R, Marcovina SM, Inazu A, Mabuchi H, Tall AR: Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation. Studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol, 1997; 17: 1045-1052","DOI":"10.1161\/01.ATV.17.6.1045"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal-Gonzalez S, Sacks FM: Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease. Arterioscler Thromb Vasc Biol, 2022; 42: 227-237","DOI":"10.1161\/ATVBAHA.121.317181"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A, Mabuchi H: Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res, 2004; 45: 448-455","DOI":"10.1194\/jlr.M300198-JLR200"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Fagan AM, Bu G, Sun Y, Daugherty A, Holtzman DM: Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem, 1996; 271: 30121-30125","DOI":"10.1074\/jbc.271.47.30121"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Paka L, Kako Y, Obunike JC, Pillarisetti S: Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E. J Biol Chem, 1999; 274: 4816-4823","DOI":"10.1074\/jbc.274.8.4816"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Ji ZS, Dichek HL, Miranda RD, Mahley RW: Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem, 1997; 272: 31285-31292","DOI":"10.1074\/jbc.272.50.31285"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Saxena U, Ferguson E, Bisgaier CL: Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J Biol Chem, 1993; 268: 14812-14819","DOI":"10.1016\/S0021-9258(18)82406-1"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Miwa K, Inazu A, Kawashiri M, Nohara A, Higashikata T, Kobayashi J, Koizumi J, Nakajima K, Nakano T, Niimi M, Mabuchi H, Yamagishi M: Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta, 2009; 402: 19-24","DOI":"10.1016\/j.cca.2008.12.012"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Autran D, Attia N, Dedecjus M, Durlach V, Girard-Globa A: Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment. Atherosclerosis, 2000; 153: 453-460","DOI":"10.1016\/S0021-9150(00)00428-7"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Matsuura F, Wang N, Chen W, Jiang XC, Tall AR: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest, 2006; 116: 1435-1442","DOI":"10.1172\/JCI27602"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Zhang J, Niimi M, Yang D, Liang J, Xu J, Kimura T, Mathew AV, Guo Y, Fan Y, Zhu T, Song J, Ackermann R, Koike Y, Schwendeman A, Lai L, Pennathur S, Garcia-Barrio M, Fan J, Chen YE: Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits. Arterioscler Thromb Vasc Biol, 2017; 37: 1068-1075","DOI":"10.1161\/ATVBAHA.117.309114"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Wang SP, Daniels E, Chen Y, Castro-Perez J, Zhou H, Akinsanya KO, Previs SF, Roddy TP, Johns DG: In vivo effects of anacetrapib on pre\u03b2HDL: improvement of HDL remodeling without effects on cholesterol absorption. J Lipid Res, 2013; 54: 2858-2865","DOI":"10.1194\/jlr.M041541"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, Adelman SJ, Nissen SE, Rader DJ: Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib. J Am Coll Cardiol, 2015; 66: 2201-2210","DOI":"10.1016\/j.jacc.2015.09.013"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Metzinger MP, Saldanha S, Gulati J, Patel KV, El-Ghazali A, Deodhar S, Joshi PH, Ayers C, Rohatgi A: Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial. J Am Heart Assoc, 2020; 9: e018136","DOI":"10.1161\/JAHA.120.018136"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Kurano M, Hara M, Ikeda H, Tsukamoto K, Yatomi Y: Involvement of CETP (Cholesteryl Ester Transfer Protein) in the Shift of Sphingosine-1-Phosphate Among Lipoproteins and in the Modulation of its Functions. Arterioscler Thromb Vasc Biol, 2017; 37: 506-514","DOI":"10.1161\/ATVBAHA.116.308692"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM, von Eckardstein A: Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis, 2011; 219: 855-863","DOI":"10.1016\/j.atherosclerosis.2011.08.049"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Chantepie S, Bochem AE, Chapman MJ, Hovingh GK, Kontush A: High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity. PLoS One, 2012 ; 7: e49336","DOI":"10.1371\/journal.pone.0049336"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Gomaraschi M, Ossoli A, Pozzi S, Nilsson P, Cefal\u00f9 AB, Averna M, Kuivenhoven JA, Hovingh GK, Veglia F, Franceschini G, Calabresi L: eNOS activation by HDL is impaired in genetic CETP deficiency. PLoS One, 2014; 9: e95925","DOI":"10.1371\/journal.pone.0095925"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Han S, Levoci L, Fischer P, Wang SP, Gagen K, Chen Y, Xie D, Fisher T, Ehrhardt AG, Peier AM, Johns DG: Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein. Biochim Biophys Acta, 2013; 1831: 825-833","DOI":"10.1016\/j.bbalip.2012.12.008"},{"key":"65","doi-asserted-by":"crossref","unstructured":"66) Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, H\u00f3lm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, K\u00f6nig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Sch\u00e4fer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O\u2019Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S: Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, 2012; 380: 572-580","DOI":"10.1016\/S0140-6736(12)60312-2"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67) Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y: A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med, 1998; 27; 659-667","DOI":"10.1006\/pmed.1998.0340"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68) Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, Arai T, Yanagi K, Takami S, Menju M, Ishigami M, Yoshida Y, Kameda-Takemura K, Hayashi K, Matsuzawa Y; Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol, 1995; 15: 1849-1856","DOI":"10.1161\/01.ATV.15.11.1849"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69) Nakamura H, Mizuno K for the MEGA Study Group: Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study. Lipids in Health and Disease, 2014; 13: 133","DOI":"10.1186\/1476-511X-13-133"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70) Hirata A, Sugiyama D, Watanabe M, Tamakoshi A, Iso H, Kotani K, Kiyama M, Yamada M, Ishikawa S, Murakami Y, Miura K, Ueshima H, Okamura T; Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH\u2013JAPAN) Research Group: Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43,407 individuals: The EPOCH-JAPAN study. J Clin Lipidol, 2018; 12: 674-684","DOI":"10.1016\/j.jacl.2018.01.014"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71) van der Tuin SJ, K\u00fchnast S, Berb\u00e9e JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y: Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. J Lipid Red, 2015; 56: 2085-2093","DOI":"10.1194\/jlr.M057794"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72) Miyosawa K, Watanabe Y, Murakami K, Murakami T, Shibata H, Iwashita M, Yamazaki H, Yamazaki K, Ohgiya T, Shibuya K, Mizuno K, Tanabe S, Singh SA, Aikawa M: New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism. Am J Physiol Endocrinol Metab, 2015; 309: E177-E190","DOI":"10.1152\/ajpendo.00528.2014"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73) Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L, Tohyama J, Johnson-Levonas AO, Wagner JA, Holleran S, Obunike J, Liu Y, Ramakrishnan R, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ: Anacetrapib lowers LDL by increasing apoB clearance in mildly hypercholesteolemic subjects. J Clin Invest, 2015; 125: 2510-2522","DOI":"10.1172\/JCI80025"},{"key":"73","doi-asserted-by":"crossref","unstructured":"74) Dong B, Singh AB, Fung C, Kan K, Liu J: CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism. Atherosclerosis, 2014; 235: 449-462","DOI":"10.1016\/j.atherosclerosis.2014.05.931"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75) Krauss RM, Wojnooski K, Orr J, Geaney JC, Pinto CA, Liu Y, Wagner JA, Luk JM, Johnson-Levonas AO, Anderson MS, Dansky HM: Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res, 2012; 53: 540-547","DOI":"10.1194\/jlr.M018010"},{"key":"75","doi-asserted-by":"crossref","unstructured":"76) Quinet E, Tall A, Ramakrishnan R, Rudel L: Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins. J Clin Invest, 1991; 87: 1559-1566","DOI":"10.1172\/JCI115169"},{"key":"76","doi-asserted-by":"crossref","unstructured":"77) Sakai N, Matsuzawa Y, Hirano K, Yamashita S, Nozaki S, Ueyama Y, Kubo M, Tarui S: Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb, 1991; 11: 71-79","DOI":"10.1161\/01.ATV.11.1.71"},{"key":"77","doi-asserted-by":"crossref","unstructured":"78) Arai H, Teramoto T, Daida H, Ikewaki K, Maeda Y, Nakagomi M, Shirakawa M, Kakikawa T, Numaguchi H, Johnson-Levonas AO, Vaidya S, Blaustein RO: Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapibin Japanese patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2016; 249: 215-223","DOI":"10.1016\/j.atherosclerosis.2016.03.017"},{"key":"78","doi-asserted-by":"crossref","unstructured":"79) Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ: Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, 2015; 386: 452-460","DOI":"10.1016\/S0140-6736(15)60158-1"},{"key":"79","doi-asserted-by":"crossref","unstructured":"80) Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML: Lipoprotein (a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor. J Biol Chem, 2015; 290: 11649-11662","DOI":"10.1074\/jbc.M114.611988"},{"key":"80","doi-asserted-by":"crossref","unstructured":"81) Castro-Perez J, Briand F, Gagen K, Wang SP, Chen Y, McLaren DG, Shah V, Vreeken RJ, Hankemeier T, Sulpice T, Roddy TP, Hubbard BK, Johns DG: Anacetrapib promotes reverse cholesterol and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res, 2011; 52: 1965-1973","DOI":"10.1194\/jlr.M016410"},{"key":"81","doi-asserted-by":"crossref","unstructured":"82) Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C: Modulating cholesteryl ester transfer protein activity maintains efficient pre\u03b21-HDL formation and increases reverse cholesterol transport. J Lipid Res, 2010; 51: 3443-3454","DOI":"10.1194\/jlr.M008706"},{"key":"82","doi-asserted-by":"crossref","unstructured":"83) Clerc RG, Stauffer A, Weibel F, Hainaut E, Perez A, Hoflack JC, B\u00e9nardeau A, Pflieger P, Garriz JM, Funder JW, Capponi AM, Niesor EJ: Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J Hypertension, 2010; 28: 1676-1686","DOI":"10.1097\/HJH.0b013e32833b1f8e"},{"key":"83","doi-asserted-by":"crossref","unstructured":"84) Simic B, Hermann M, Shaw SG, Bigler L, Stalder U, D\u00f6rries C, Besler C, L\u00fcscher TF, Ruschitzka F: Torcetrapib impairs endothelial function in hypertension. Eur Heart J, 2012; 33: 1615-1624","DOI":"10.1093\/eurheartj\/ehr348"},{"key":"84","doi-asserted-by":"crossref","unstructured":"85) Cao G, Beyer TP, Zhang Y, Schmidt RJ, Chen YQ, Cockerham SL, Zimmerman KM, Karathanasis SK, Cannady EA, Fields T, Mantlo NB: Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res, 2011; 52: 2169-2176","DOI":"10.1194\/jlr.M018069"},{"key":"85","doi-asserted-by":"crossref","unstructured":"86) Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, Adelman SJ, Nissen SE, Rader DJ: Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations are Increased in Dyslipidemic Patients Treated with Evacetrapib. J Am Coll Cardiol, 2015; 66: 2201-2210","DOI":"10.1016\/j.jacc.2015.09.013"},{"key":"86","doi-asserted-by":"crossref","unstructured":"87) Tardif JC, Pfeffer MA, Kouz S, Koenig W, Maggioni AP, McMurray JJV, Mooser V, Waters DD, Gr\u00e9goire JC, L\u2019Allier PL, Wouter Jukema J, White HD, Heinonen T, Black DM, Laghrissi-Thode F, Levesque S, Guertin MC, Dub\u00e9 MP; dal-GenE Investigators: Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J, 2022; 43: 3947-3956","DOI":"10.1093\/eurheartj\/ehac374"},{"key":"87","doi-asserted-by":"crossref","unstructured":"88) K\u00fchnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, L\u00fcscher TF, Willems van Dijk K, Rensen PC, Jukema JW, Princen HM: Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesteol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J, 2015; 36: 39-48","DOI":"10.1093\/eurheartj\/ehu319"},{"key":"88","doi-asserted-by":"crossref","unstructured":"89) Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, Alp NJ, Davidson MH: Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nature Med, 2022; 28: 1672-1678","DOI":"10.1038\/s41591-022-01936-7"},{"key":"89","doi-asserted-by":"crossref","unstructured":"90) Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH: Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Current Atherosclerosis Reports, 2024; 26: 35-44","DOI":"10.1007\/s11883-023-01184-1"},{"key":"90","doi-asserted-by":"crossref","unstructured":"91) Bell TA 3rd, Graham MJ, Lee RG, Mullick AE, Fu W, Norris D, Crooke RM: Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-\/- mice. J Lipid Res, 2013; 54: 2647-2657","DOI":"10.1194\/jlr.M036509"},{"key":"91","doi-asserted-by":"crossref","unstructured":"92) Morton RE, Izem L: Modification of CETP function by changing its substrate preference: a new paradigm for CETP drug design. J Lipid Res, 2015; 56: 612-619","DOI":"10.1194\/jlr.M056333"},{"key":"92","doi-asserted-by":"crossref","unstructured":"93) \u00d8lnes AS, Teigen M, LaerdahlI JK, Leren TP, Str\u00f8mITB, Bjune K: Variants in the CETP gene affect levels of HDL cholesterol by reducing the amount, and not the specific lipid transfer activity, of secreted CETP. PLoS One, 2023; 18: e0294764","DOI":"10.1371\/journal.pone.0294764"},{"key":"93","doi-asserted-by":"crossref","unstructured":"94) Saito K, Kobori K, Hashimoto H, Ito S, Manabe M, Yokoyama S: Epitope mapping for the anti-rabbit cholesteryl ester transfer protein monoclonal antibody that selectively inhibits triglyceride transfer. J Lipid Res, 1999; 40: 2013-2021","DOI":"10.1016\/S0022-2275(20)32425-1"},{"key":"94","doi-asserted-by":"crossref","unstructured":"95) Liaw YW, Lin CY, Lai YS, Yang TC, Wang CJ, Whang-Peng J, Liu LF, Lin CP, Nieh S, Lu SC, Hwang J: A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One, 2014; 9: e111529","DOI":"10.1371\/journal.pone.0111529"},{"key":"95","doi-asserted-by":"crossref","unstructured":"96) Hu W, Feng H, Liu Y, Xu X, Zhou P, Sun Z, Tao X, Yang J, Wu J, Qu C & Liu Z: Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention. Human Vaccines & Immunotherapeutics, 2025; 21: 2462466","DOI":"10.1080\/21645515.2025.2462466"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/8\/32_RV22037\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:25:43Z","timestamp":1754108743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/8\/32_RV22037\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv22037","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"RV22037"}}